How Cohen was paid
$2.7M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|
| Joshua CohenCo-Chief Executive Officer and Director | $686,200 | $650,226 | $817,783 | $548,098 | $17,500 | $2,719,807 |
| Justin KleeCo-Chief Executive Officer and Director | $686,200 | $650,226 | $817,783 | $548,098 | $17,500 | $2,719,807 |
| James FratesChief Financial Officer | $540,600 | $246,996 | $311,148 | $259,083 | $17,500 | $1,375,327 |
| Camille L. Bedrosian, M.D.Chief Medical Officer | $575,000 | $246,996 | $312,872 | $275,569 | $157,237 | $1,567,674 |
What changed and why
- $6.5MCo-CEO total compensation decreased from $6,496,255 in 2024 to $2,719,807 in 2025 following restructuring.
- Base salaries for the executive leadership team were held steady for 2025.
- One-time performance-based restricted stock units were granted to executives to incentivize avexitide milestones.
- $0PSUs granted in 2025 were assigned a grant date fair value of $0 as performance conditions were not probable.
- 58%The Say-on-Pay vote received approximately 58% shareholder support at the previous annual meeting.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.